Neurological effects of MIF-1, MSH, and opiate peptides in clinical studies.
D000978:Antiparkinson Agents; D001921:Brain / Q000187:drug effects; D005405:D-Ala(2),MePhe(4),Met(0)-ol-enkephalin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D003863:Depression / Q000188:drug therapy; D004359:Drug Therapy, Combination; D004569:Electroencephalography; D004723:Endorphins / Q000494:pharmacology* / Q000627:therapeutic use*; D005074:Evoked Potentials, Visual / Q000187:drug effects; D005260:Female; D006801:Humans; D009075:MSH Release-Inhibiting Hormone / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D009074:Melanocyte-Stimulating Hormones / Q000494:pharmacology* / Q000627:therapeutic use*; D009269:Nalorphine / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010446:Peptide Fragments / Q000494:pharmacology
D000978:Antiparkinson Agents; D004723:Endorphins; D010446:Peptide Fragments; D005405:D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; D009074:Melanocyte-Stimulating Hormones; D009075:MSH Release-Inhibiting Hormone; D009269:Nalorphine